Looking at some ROIC (Return on Invested Capital) numbers, Mayne Pharma Group Limited (ASX:MYX)’s ROIC Quality Score is 2.808218. ROIC is a profitability ratio that measures the return that an investment generates for those providing capital. ROIC helps show how efficient a firm is at turning capital into profits. This formula is calculated by 5 year average Return on Invested Capital (ROIC) / Standard Deviation of the 5 year ROIC. The higher the ratio, the better as a higher score indicates a more stable return on invested capital.

Investors studying the fundamentals might be conducting in-depth company research before deciding when to purchase a particular stock. The investor checklist may include studying the scope of a company’s competitive industry advantage, examining company management, and trying to get a general feel if the stock is valued properly. Once the decision is made that the company is a good fit for the portfolio, it may be wise to assess whether or not current conditions and price levels indicate proper levels for share purchase. The timing of purchasing a researched stock obviously comes with some level of trepidation. Investors will only know in the future whether they got in at the right price. A stock that looks very attractive today may not be as attractive in the future. Sometimes the investor will just have to trust their research and instinct when purchasing shares.

Some of the best financial predictions are formed by using a variety of financial tools. The Price Range 52 Weeks is one of the tools that investors use to determine the lowest and highest price at which a stock has traded in the previous 52 weeks. The Price Range of Mayne Pharma Group Limited (ASX:MYX) over the past 52 weeks is 0.617000. The 52-week range can be found in the stock’s quote summary.

Mayne Pharma Group Limited (ASX:MYX) presently has a current ratio of 2.67. The current ratio, also known as the working capital ratio, is a liquidity ratio that displays the proportion of current assets of a business relative to the current liabilities. The ratio is simply calculated by dividing current liabilities by current assets. The ratio may be used to provide an idea of the ability of a certain company to pay back its liabilities with assets. Typically, the higher the current ratio the better, as the company may be more capable of paying back its obligations.

Mayne Pharma Group Limited (ASX:MYX)’s Leverage Ratio was recently noted as 0.200179. This ratio is calculated by dividing total debt by total assets plus total assets previous year, divided by two. The leverage of a company is relative to the amount of debt on the balance sheet. This ratio is often viewed as one measure of the financial health of a firm.

The price to book ratio or market to book ratio for Mayne Pharma Group Limited (ASX:MYX) currently stands at 1.038973. The ratio is calculated by dividing the stock price per share by the book value per share. This ratio is used to determine how the market values the equity. A ratio of under 1 typically indicates that the shares are undervalued. A ratio over 1 indicates that the market is willing to pay more for the shares. There are often many underlying factors that come into play with the Price to Book ratio so all additional metrics should be considered as well.

**FCF**

Free Cash Flow Growth (FCF Growth) is the free cash flow of the current year minus the free cash flow from the previous year, divided by last year’s free cash flow. The FCF Growth of Mayne Pharma Group Limited (ASX:MYX) is 0.457286. Free cash flow (FCF) is the cash produced by the company minus capital expenditure. This cash is what a company uses to meet its financial obligations, such as making payments on debt or to pay out dividends. The Free Cash Flow Score (FCF Score) is a helpful tool in calculating the free cash flow growth with free cash flow stability – this gives investors the overall quality of the free cash flow. The FCF Score of Mayne Pharma Group Limited (ASX:MYX) is 1.670028. Experts say the higher the value, the better, as it means that the free cash flow is high, or the variability of free cash flow is low or both.

**GM Score**

The Gross Margin Score is calculated by looking at the Gross Margin and the overall stability of the company over the course of 8 years. The score is a number between one and one hundred (1 being best and 100 being the worst). The Gross Margin Score of Mayne Pharma Group Limited (ASX:MYX) is 46.00000. The more stable the company, the lower the score. If a company is less stable over the course of time, they will have a higher score.

**FCF**

Free Cash Flow Growth (FCF Growth) is the free cash flow of the current year minus the free cash flow from the previous year, divided by last year’s free cash flow. The FCF Growth of Mayne Pharma Group Limited (ASX:MYX) is 0.457286. Free cash flow (FCF) is the cash produced by the company minus capital expenditure. This cash is what a company uses to meet its financial obligations, such as making payments on debt or to pay out dividends. The Free Cash Flow Score (FCF Score) is a helpful tool in calculating the free cash flow growth with free cash flow stability – this gives investors the overall quality of the free cash flow. The FCF Score of Mayne Pharma Group Limited (ASX:MYX) is 1.670028. Experts say the higher the value, the better, as it means that the free cash flow is high, or the variability of free cash flow is low or both.

**Rank**

The ERP5 Rank is an investment tool that analysts use to discover undervalued companies. The ERP5 looks at the Price to Book ratio, Earnings Yield, ROIC and 5 year average ROIC. The ERP5 of Mayne Pharma Group Limited (ASX:MYX) is 7589. The lower the ERP5 rank, the more undervalued a company is thought to be.

**Value**

The Value Composite One (VC1) is a method that investors use to determine a company’s value. The VC1 of Mayne Pharma Group Limited (ASX:MYX) is 48. A company with a value of 0 is thought to be an undervalued company, while a company with a value of 100 is considered an overvalued company. The VC1 is calculated using the price to book value, price to sales, EBITDA to EV, price to cash flow, and price to earnings. Similarly, the Value Composite Two (VC2) is calculated with the same ratios, but adds the Shareholder Yield. The Value Composite Two of Mayne Pharma Group Limited (ASX:MYX) is 55.

Investing in the stock market often requires individuals to gauge how much risk they are willing to take on for potential reward. Piling on too much risk can put the investor out of their comfort zone. On the flip side, taking on too little risk may not provide the opportunity to receive enough returns to achieve previously stated goals. Finding that perfect balance may come with some first-hand experience that includes some trial and error.

A company with a value of 0 is thought to be an undervalued company, while a company with a value of 100 is considered an overvalued company. The VC1 is calculated using the price to book value, price to sales, EBITDA to EV, price to cash flow, and price to earnings. Similarly, the Value Composite Two (VC2) is calculated with the same ratios, but adds the Shareholder Yield.

**Volatility**

Stock volatility is a percentage that indicates whether a stock is a desirable purchase. Investors look at the Volatility 12m to determine if a company has a low volatility percentage or not over the course of a year. The Volatility 12m of Mayne Pharma Group Limited (ASX:MYX) is 49.191300. This is calculated by taking weekly log normal returns and standard deviation of the share price over one year annualized. The lower the number, a company is thought to have low volatility. The Volatility 3m is a similar percentage determined by the daily log normal returns and standard deviation of the share price over 3 months. The Volatility 3m of Mayne Pharma Group Limited (ASX:MYX) is 52.108000. The Volatility 6m is the same, except measured over the course of six months. The Volatility 6m is 46.161300.

From time to time, investors may need to decide when to sell a winner. This can be one of the tougher portfolio decisions to make. When a winning stock keeps rising, it can be tough to part with it. Investors may become hesitant to sell because they don’t want to miss out on greater profits in the future. Sometimes this strategy will work, and other times investors may be watching all previous gains evaporate. Being able to sell a winner can provide obvious profits, and it may even be a confidence booster for the average investor. On the flip side, investors may also be faced with the decision of when to sell a loser. Even the most researched trades can go sour. Being able to detach from the trade mentally can end up saving the investor more grief down the line. Holding onto a stock with the hopes of a giant turnaround can be a recipe for portfolio disaster. Being able to cut losses is just as much a part of the process as being able to cash in winners. Learning from mistakes and being able to wipe the slate clean can help the investor be better prepared for future endeavors in the markets.